Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of Single and Multiple Administration of Oral PA3670 Tablets in Chinese Healthy Subjects and the Effect of Food on Pharmacokinetics
Latest Information Update: 19 Apr 2024
At a glance
- Drugs PA 3670 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Zhejiang Palo Alto Pharmaceuticals
Most Recent Events
- 15 Apr 2024 Status changed from recruiting to completed.
- 17 May 2023 New trial record